Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade.

Eric J MillerTracy L RoseBenjamin L Maughan Matthew I Milowsky Mehmet Asim BilenBradley C CarthonXin GaoSuthee RapisuwonQianqian ZhaoMenggang YuNeeraj AgarwalMatthew D Galsky

Published in: Cancer (2024)

High dose CTLA-4 blockade in patients with PD-1/PD-L1-resistant metastatic urothelial cancer has modest activity and is associated with treatment-related toxicity similar to prior reports.

Keyphrases

papillary thyroid
high dose
squamous cell
high grade
squamous cell carcinoma
small cell lung cancer
low dose
lymph node metastasis
oxidative stress
childhood cancer
stem cell transplantation
young adults
adverse drug
replacement therapy